Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03698994
Title Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

rhabdoid cancer

non-Hodgkin lymphoma

histiocytic and dendritic cell cancer

osteosarcoma

germ cell cancer

neuroblastoma

high grade glioma

medulloblastoma

sarcoma

Ewing sarcoma

brain ependymoma

Advanced Solid Tumor

central nervous system cancer

hepatoblastoma

rhabdomyosarcoma

neuroectodermal tumor

nephroblastoma

Therapies

Ulixertinib

Age Groups: child | adult
Covered Countries USA

Additional content available in CKB BOOST